

Pharma **POOL**

Kevin **GUTHRIE**

Thom **ROWLAND**

Solvay Promotes VPs

Solvay Pharmaceuticals, Marietta, Ga., a pharmaceutical company focused on cardiology, gastroenterology, mental health, women's health, and select specialized markets, has promoted Kevin Guthrie to VP of commercial operations, neuroscience, responsible for managing all sales and marketing activities of the neuroscience business unit.

He previously served as director, sales operations.

Mr. Guthrie holds a bachelor's degree in business administration from Murray State University.

Thom Rowland has been promoted to VP of commercial operations. He is responsible for managing all aspects of the company's gastroenterology and women's health business units.

Mr. Rowland joined Solvay in 2000 as senior product manager for Luvox and most recently served as business director of GI marketing.

He earned his bachelor's degree in finance from Metropolitan State University.

Karen **KATEN**

Jeff **KINDLER**

Alan **LEVIN**

David **SHEDLARZ**

Pfizer Announces Executive Appointments

Pfizer, New York, has announced that

Karen Katen, Jeff Kindler, and David Shedlarz have become vice chairmen. The three also have been appointed to the newly formed executive committee, responsible for the strategic direction and operations of the pharmaceutical company.

Additionally, Ms. Katen, formerly president of Pfizer Global Pharmaceuticals, has been promoted to president of Pfizer Human Health.

She joined Pfizer in 1974 after receiving a MBA from the University of Chicago.

Mr. Kindler, who oversees the company's legal affairs worldwide and serves as general counsel, has assumed management responsibility for corporate affairs.

He came to Pfizer in 2002 from McDonald's, where he was president of partner brands.

Mr. Kindler earned his J.D. from Harvard Law School.

Mr. Shedlarz, who oversees operations including finance, strategic planning, global sourcing, and information systems, has assumed responsibility for Pfizer's human resources department.

He received his MBA from New York University and has been with Pfizer since 1976, serving for the last 10 years as chief financial officer, a position that Alan Levin, senior VP, has assumed.

Mr. Levin, a CPA, earned his M.S. in accounting from New York University.

Christopher **KELLY**

Winston K.C. **LAM**

Dr. James F. **MCLEOD**

Joy G. **SCHMITT**

Schering-Plough Announces Additions to Staff

Schering-Plough, a global science-based healthcare company based in Kenilworth,

N.J., has named Christopher Kelly VP, global information technology, global supply chain/global quality operations. He provides strategic information technology leadership for supply-chain and quality systems initiatives globally.

Mr. Kelly has joined Schering-Plough from IBM Business Consulting Services, where he was a partner and led the U.S. pharmaceutical industry technology strategy and management practice.

He holds a diploma in management studies from Staffordshire Polytechnic and a MBA from Staffordshire University Business School in the United Kingdom.

Winston K. C. Lam has joined Schering-Plough as VP and associate general counsel, business development and strategic alliances.

In this newly created role, Mr. Lam provides strategic and legal leadership to business development transactions.

He has joined Schering-Plough from McKesson, where he was senior VP, business development, for the medical-surgical unit and a member of the unit's operating team.

Mr. Lam holds a B.A. in history from Carleton College, a J.D. from Cornell University, and a MBA from the University of Chicago.

James F. McLeod, M.D., has been named VP of global clinical development, early clinical research, and experimental medicine, for the Schering-Plough Research Institute.

He oversees clinical pharmacology activities across early-development projects, chairs the committee responsible for decisions on initial clinical trials of experimental medicines, and serves as a member of the early-development committee. As part of his responsibilities, Dr. McLeod provides clinical guidance in the linkage of preclinical models and early clinical experience.

Dr. McLeod previously was with Novartis Pharmaceuticals, where he was VP of translational medicine and clinical pharmacology, clinical development, and medical affairs.

He holds a B.S. from Rensselaer Polytechnic Institute and a M.D. from the University of Connecticut.



Joy G. Schmitt has been named director of global product communications and advocacy relations. She serves as the key relationship manager with the HIV/AIDS and hepatitis C patient communities. She also is responsible for public relations and advocacy activities supporting Schering-Plough's global oncology franchise.

Ms. Schmitt most recently worked at Genta as director and head of public relations.

She holds a B.A. in English from The College of William and Mary.

Biotech POOL

Dr. Joshua **BOGER**

Dr. Victor A.

HARTMANN

Vertex Makes Senior Management Changes



Vertex Pharmaceuticals, Cambridge, Mass., has announced that Joshua Boger, Ph.D., has assumed the role of president, following the retirement of Vicki Sato, Ph.D. Vertex discovers, develops, and sells small-molecule inhibitors for the treatment of diseases, such as HIV/AIDS, cancer, and hepatitis C.

Dr. Boger previously served as chairman and CEO of the global biotechnology company and continues to hold those positions.



Victor A. Hartmann, M.D., has been named to the newly created position of executive VP, strategic and corporate development.

Dr. Hartmann most recently served as senior VP, head of global business development and licensing, at Novartis Pharma. He holds a B.S. in biology from Macalester College, and he earned his medical degree as a specialist in internal medicine at the University of Bonn, Germany.

Dr. Dean **FALB**

Stryker Names VP, Research and Development



Stryker Biotech, a division of Stryker Corp., which develops new products for bone repair, has appointed Dean Falb, Ph.D., as VP of research and development.

Dr. Falb is responsible for ongoing development activities and new product development initiatives at the Kalamazoo, Mich.-based biotechnology company.

Most recently, he was VP of research and development for VisEn Medical.

Dr. Falb received a B.S. in chemistry from Purdue University and a Ph.D. in biochemistry and molecular biology from Harvard University.

Mary **FISHER**

John **LIBRIE**

Tierney **SACCAVINO**

Acorda Promotes Senior Managers



Acorda Therapeutics, Hawthorne, N.Y., has announced the promotions of several senior managers.

Mary Fisher has been appointed chief operating officer, responsible for the biotechnology company's marketing, sales, and communications functions, as well as business development and commercial manufacturing.

Ms. Fisher previously served as executive VP of commercial operations.

John Librie has been promoted to VP of sales and marketing. He directs the sales, marketing, and commercial operations for Zanaflex.

Tierney Saccavino has been promoted to VP of corporate communications. Ms. Saccavino's group is responsible for corporate communications, medical communications, and consumer advocacy.

Dr. Alan **JACOBS**

StemCells Names Chief Medical Officer and VP, Clinical Research, Neural Program



StemCells, Palo Alto, Calif., has appointed Alan Jacobs, M.D., Ph.D., as chief medical officer and VP of clinical research, neural program. The biotechnology company focuses on the discovery, development, and commercialization of stem-cell-based therapies for diseases of the nervous system, liver, and pancreas.

Dr. Jacobs leads the company's adult human neural stem-cell program through the clinical-development process.

He formerly was the senior director of clinical development at Titan Pharmaceuticals.

Dr. Jacobs earned his Ph.D. from the University of Pennsylvania, David Mahoney Institute of Neuroscience, and his M.D. from the University of Pennsylvania, School of Medicine.

He completed a neurosurgery residency at the University of California, San Francisco Medical Center. Additionally, he holds a M.S. in electrical engineering from Stanford University.

James **SHARPE**

CEO Appointed at Astralis

James Sharpe has taken the position of CEO at Astralis, Fairfield, N.J., a biotechnology company focused on developing treatments for immune system disorders and skin diseases.

Before joining the company, Mr. Sharpe served as president and founder of Ankyr Consulting.

He holds a B.S. in chemistry from Union College and a MBA in marketing and finance from the University of Rochester.

Biopharmaceutical POOL

Armando **ANIDO**

Charles F. **KATZER**

Dr. Peter A. **KIENER**

Bernardus N.M.

MACHIELSE

Edward T. **MATHERS**

Linda J. **PETERS**

MedImmune Hires and Promotes

MedImmune, Gaithersburg, Md., a life-sciences company focused on infectious diseases, cancer, and inflammatory diseases, has announced several key leadership changes.

Armando Anido, R.Ph., has been promoted to executive VP, sales and marketing, responsible for overseeing the company's global commercial activities. Mr. Anido joined MedImmune in 1999 as senior VP, sales and marketing.

A registered pharmacist, Mr. Anido holds a bachelor's degree in pharmacy and a MBA from West Virginia University.

Charles F. Katzer has assumed responsibility for global vaccine manufacturing operations in his new position as VP of vaccine manufacturing. Previously, he was VP and site director of manufacturing activities.

He earned his bachelor's degree in zoology from the University of Wisconsin.

Peter A. Kiener, D.Phil., has been promoted to senior VP, research, responsible for the company's global research activities. Before joining MedImmune in 2001, Dr. Kiener spent 18 years with Bristol-Myers Squibb's pharmaceutical research division.

He holds a B.S. in chemistry, with honors, from Lancaster University in the United Kingdom, and he earned his doctorate of philosophy in biochemistry from Oxford University, Sir William Dunn School of Pathology.

Bernardus N.M. Machielse, senior VP, operations, has assumed responsibility for all manufacturing and supply-chain operations. He has retained responsibility for MedImmune's quality operations, a position he has held since joining the company in 1999. He holds a B.S. in medical biology and a M.S. in biochemistry from the University of Utrecht, the Netherlands.

Edward T. Mathers has been named senior VP, corporate development, responsible for licensing and business development activities. He joined MedImmune in 2002 from Inhale Therapeutic Systems, where he was VP of marketing and corporate licensing and acquisitions. Mr. Mathers holds a bachelor's degree in chemistry from North Carolina State University.

Linda J. Peters has joined the management team as senior VP, regulatory affairs. She is responsible for defining and orchestrating MedImmune's global regulatory strategy. Ms. Peters has joined MedImmune from Baxter Healthcare, where she was VP of global regulatory affairs for the bioscience and renal divisions. She earned her B.S. and M.S. degrees in animal science from Southern Illinois University. She also holds a MBA from the J.L. Kellogg School of Management at Northwestern University.

Dr. Shripad BHAGWAT

Dr. Robert DEGROOF

Ambit Appoints Senior VPs



Ambit Biosciences, San Diego, has appointed Shripad Bhagwat, Ph.D., to the position of senior VP of drug discovery. He manages the identification and preclinical development of promising leads identified through the biopharmaceutical company's proprietary screening technologies.

Most recently, Dr. Bhagwat served as VP of drug discovery at Celgene.

He earned his Ph.D. in organic chemistry from the State University of New York at Stony Brook and conducted postdoctoral research at Columbia University.

Additionally, Robert deGroof, Ph.D., has joined Ambit as senior VP of development, responsible for advancing the company's small-molecule drug candidates into clinical trials.

Dr. deGroof has come to the biopharma-

ceutical company from Alteon, where he was senior VP, scientific affairs.

Dr. deGroof earned his Ph.D. in physiology and pharmacology from Duke University and his B.S. in electrical engineering from the University of Florida.

Dr. Abbie CELNIKER

Anna PROTOPAPAS

Dr. David SCHENKEIN

Dr. Nancy SIMONIAN

Millennium Announces Executive Appointments

Millennium Pharmaceuticals, Cambridge, Mass., has promoted and expanded the roles of several key executives. Millennium is a biopharmaceutical company focused in the therapeutic areas of oncology, cardiovascular disease, and inflammation.



Abbie Celniker, Ph.D., has an expanded role as senior VP of research and development strategy and operations, and pharmaceutical sciences. In addition to her previous responsibilities for coleading the pipeline portfolio review committee and heading development project management, Dr. Celniker now oversees pharmaceutical sciences, including process, formulations, and analytical research and development, as well as investigational quality assurance and supply operations.

Dr. Celniker has a bachelor's degree in biology from the University of California at San Diego and a Ph.D. in molecular biology from the University of Arizona.



Anna Protopapas has been promoted to senior VP, corporate development, responsible for leading Millennium's efforts in strategic alliances, product acquisitions, out-licensing, and new ventures.

Ms. Protopapas continues to be responsible for all corporate and business development activities and now is focusing on delivering on corporate and business development goals by consummating high-level alliances that support the company's path to profitability and long-term growth.

She holds a bachelor's degree in chemical engineering from Princeton University, a master's degree in chemical engineering from Massachusetts Institute of Technology, and a MBA from Stanford University.



David Schenkein, M.D., has been promoted to senior VP, clinical development, responsible for leading oncology, inflammation, and cardiovascular clinical-research efforts to develop novel therapies and directing the global medical affairs group in shaping the company's medical strategy.

He graduated from Wesleyan University and received his medical degree at State University of New York, Upstate Medical School.



Additionally, Nancy Simonian, M.D., has assumed an expanded role as senior VP of clinical, regulatory, and medical affairs. She leads an integrated medical organization that consolidates all medical functions,

including clinical development, regulatory affairs, pharmacovigilance, and global medical affairs.

She graduated from Princeton University and received her medical degree from the University of Pennsylvania School of Medicine.

Ronald G. EIDELL

NeoPharm Appoints Interim CEO



NeoPharm has appointed Ronald G. Eidell, a member of its board of directors, as interim CEO while it searches for a permanent chief executive. He replaces Gregory P. Young, who resigned in March to pursue other opportunities.

NeoPharm, based in Lake Forest, Ill., is dedicated to the research, development, and commercialization of new and innovative cancer drugs.

Mr. Eidell, who joined NeoPharm's board in November 2004, served as chair of the audit committee and was a member of the corporate governance committee before assuming this new role.

He is a partner with Tatum Partners, a national professional services firm.

Mr. Eidell received his MBA from the University of Chicago and his B.S. in business administration from Drexel University.

Sheldon GOLDBERG

Voyager Appoints Senior VP, Corporate Development

Sheldon Goldberg has taken the position of senior VP of corporate development at Voy-

ager Pharmaceutical, a biopharmaceutical company focused on diseases of aging and development. He is responsible for implementing key advocacy, business, and public-policy functions that support the Raleigh, N.C., company's novel Alzheimer's therapeutic approach and anticipated pivotal studies.

Formerly president and CEO of the Alzheimer's Association, Mr. Goldberg currently is the chairman of the board of the business venture side of AARP Services.

R. Douglas **HULSE**

Hemispherx Elects President and Chief Operating Officer

Hemispherx Biopharma, Philadelphia, a developer of immune-based, experimental therapies, has elected R. Douglas Hulse president and chief operating officer.

Mr. Hulse most recently was an executive director of The Sage Group.

Mr. Hulse graduated Phi Beta Kappa from Princeton University with a cum laude degree in chemistry. He earned S.M. degrees in management and chemical engineering from M.I.T.

Dr. Leander **LAUFFER**

Trubion Names Senior VP, Business Development and Corporate Strategy

Trubion Pharmaceuticals has named Leander Lauffer, Ph.D., senior VP of business development and corporate strategy. The Seattle-based biopharmaceutical company focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. Dr. Lauffer is responsible for executing strategic alliances to advance Trubion's discovery and development plans.

Previously, Dr. Lauffer was VP of business development for Chiron's biopharmaceuticals division.

Dr. Lauffer earned a master's degree in biology from Konstanz University in Germany and a Ph.D. in biology from Free University in Berlin. He held postdoctoral fellowships at the University of California, San Francisco, and Massachusetts General Hospital.

Dr. Mary **OSBAKKEN**

Inotek Hires Chief Medical Officer

Inotek Pharmaceuticals, Beverly, Mass., has named Mary Osbakken, M.D., Ph.D. to the position of chief medical officer, responsible for the company's clinical development strategy and global clinical operations.

Dr. Osbakken has joined the multinational biopharmaceutical firm, which is focused on discovery research and the development of

novel pharmaceutical technologies, from Aventis, where she most recently served as VP of intercontinental clinical development and chair of Aventis' product realization protocol review committee.

She holds M.S. degrees in physiology and biomedical engineering from the University of Illinois and Drexel University, respectively. She completed her Ph.D. in physiology at Thomas Jefferson University and her M.D. at Temple University.

Randall B. **RIGGS**

BioCryst Strengthens Management Team



Randall B. Riggs has joined BioCryst Pharmaceuticals as VP of business development, responsible for managing licensing and business development activities for the company's leading product candidates. BioCryst, based

in Birmingham, Ala., designs, optimizes, and develops small-molecule pharmaceuticals.

Mr. Riggs most recently was VP of business development at TransMolecular.

He holds a bachelor's of business administration from Texas A&M University and a MBA from the University of Houston.

Joseph A. **SCHLITZ**

Adolor Creates VP of Sales Position

Joseph A. Schlitz has been named VP of sales at Adolor, Exton, Pa., a biopharmaceutical company focused on prescription pain management medications. In the newly created position, he is responsible for developing and managing the company's sales organization.

Mr. Schlitz most recently served as an area VP at Schering-Plough. He earned a master's degree in business management/marketing from Northwestern University's J.L. Kellogg Graduate School of Management.

Dr. Susan Anne

WATSON

Apton Appoints Chief Scientific Officer

Apton has appointed Susan Anne Watson, Ph.D., to the newly created position of senior VP and chief scientific officer. She is responsible for overseeing research operations and executing the preclinical drug development strategy for the Philadelphia-based clinical-stage biopharmaceutical company.

Most recently, Dr. Watson was with the

University of Nottingham, United Kingdom, where she held multiple roles, including director of cancer research.

Dr. Watson completed her B.S. at the University of Leeds and her Ph.D. at the University of Nottingham. She completed postdoctoral research with AstraZeneca.

Specialty **POOL**

Robert E. **BANCROFT**

Healthpoint Hires VP, Tissue Management Marketing



Robert E. Bancroft has joined Healthpoint, Fort Worth, Texas, as VP of marketing for the tissue management division. Healthpoint, a specialty pharmaceutical company and affiliate of DFB Pharmaceuticals,

focuses on the research, development, and marketing of branded pharmaceuticals, over-the-counter drugs, and medical devices for tissue management, dermatology, and surgical.

Mr. Bancroft formerly served as senior marketing director for global Botox at Allergan.

He holds a B.S. in biology from Indiana University and a MBA in marketing and finance from the University of Southern California, Los Angeles.

Dr. Gosse B. **BRUINSMA**

Axonyx Appoints CEO

Axonyx, New York, has promoted Gosse B. Bruinsma, M.D., to the role of CEO, replacing Marvin S. Hausman. Axonyx is dedicated to developing treatments for Alzheimer's and other neurodegenerative diseases.

Dr. Hausman, who helped found the company in 1996, remains on the board of directors.

Dr. Bruinsma has been with Axonyx since 2000, when he was hired as president of its European operations. Since then, he was served as chief operating officer and, most recently, as president.

Marc **CORRADO**

EntreMed Appoints Corporate Development Leader

EntreMed has added Marc Corrado to its



senior management team as VP of corporate development. The clinical-stage pharmaceutical company based in Rockville, Md., develops therapeutics for the treatment of cancer and inflammatory diseases.

Mr. Corrado most recently was senior director of mergers and acquisitions for Aventis.

Mr. Corrado earned his J.D. at American University and his MBA from INSEAD, France.

Dr. Philip **FROST**

Dr. Eric K. **ROWINSKY**

ImClone Announces Executive Appointments

ImClone Systems has named Philip Frost, M.D., Ph.D., executive VP, chief scientific officer, and Eric K. Rowinsky, M.D., senior VP, chief medical officer. New York-based ImClone is advancing oncology care by developing and commercializing a portfolio of targeted biological treatments designed to address the medical needs of patients with a variety of cancers.

Dr. Frost's principal responsibility is to oversee all of ImClone's scientific endeavors, which encompass the company's research, clinical, and regulatory departments, among others. Dr. Frost previously served as VP of oncology and codirector of the oncology therapeutic area leadership team at Wyeth.

Dr. Frost earned his B.A. degree from Yeshiva University, his M.D. from the State University of New York at Buffalo, his Ph.D. in immunology from the Medical Research Council, Clinical Research Center in London, and he was an education fellow at Mount Sinai Hospital.

Dr. Rowinsky is responsible for the clinical development and regulatory strategies pertaining to Erbitux, an IgG1 monoclonal antibody approved for use in treating certain patients with metastatic colorectal cancer, as well as the company's various product candidates.

Before joining ImClone, Dr. Rowinsky served as the director of the Institute for Drug Development (IDD) of the Cancer Therapy and Research Center and the SBC Endowed Chair for Early Drug Development at the IDD.

He received his B.A. degree from New York University and his M.D. from the Vanderbilt University School of Medicine.

James E. **HATTERSLEY**

Antares Hires Business Development Executive

Antares Pharma has hired James E. Hat-

tersley to the position of VP of corporate business development. Antares, Exton, Pa., is a specialty pharma company focused on the growing lifestyle products sector. Mr. Hattersley focuses on building strategic relationships with new pharmaceutical partners while broadening and expanding key existing relationships.

Most recently, he served as senior director of business development at Eurand.

He earned both his M.S. in biochemistry and his bachelor's degree in neurobiology from the University of California.

Michael **LAFERRERA**

Steve **MILLER**

Marshall **RIZZO**

Barrier Builds Commercial Team

Barrier Therapeutics, a pharmaceutical company that develops and commercializes dermatology products, has added three experienced leaders to its commercial team.

Michael LaFerrera has joined Princeton, N.J.-based Barrier as VP of marketing and commercial planning. Mr. LaFerrera most recently worked at Nelson Communications (Publicis) as executive VP, managing director.

He earned a B.S. in business administration, with a concentration in marketing, from the University of Delaware.

Steve Miller has been hired as VP of sales. Mr. Miller previously served as executive director, business development, at Innovex, a division of Quintiles Transnational.

He is a graduate from the MBA program at Carnegie Mellon University and the U.S. Military Academy at West Point.

Additionally, Barrier has appointed Marshall "Scott" Rizzo global head, supply chain and trade relations. Most recently, Mr. Rizzo was employed by Roche as the director of supply management.

Mr. Rizzo holds a MBA and a master's degree in manufacturing management from Pennsylvania State University.

Peter A. **LANKAU**

Endo Appoints CEO

Endo Pharmaceuticals Holdings, Chadds Ford, Pa., has appointed Peter A. Lankau president and CEO. Mr. Lankau previously served as president and chief operating officer of the specialty pharmaceutical company focused on pain management products. Mr. Lankau also has been appointed to the board of directors.

Carol A. Ammon, the previous CEO, continues to serve Endo as chairman of the board of directors.

Ted G. **SCHWARZ**

SkinMedica Names VP, Cosmeceutical Sales and Marketing



SkinMedica, Carlsbad, Calif., a specialty pharmaceutical company developing and marketing dermatology products, has appointed Ted G. Schwarz VP of cosmeceutical sales and marketing. Mr. Schwarz is

responsible for marketing, sales, and other commercial functions for the company's growing cosmeceutical line of products.

He joined SkinMedica from La Roche-Posay, the cosmeceutical division of L'Oreal, where he was VP of sales. He holds a B.A. in marketing from Michigan State University.

Greg **VONTZ**

Tom **WIGGANS**

Connetics Announces Leadership Changes



Greg Vontz has been appointed to the position of president of Connetics, a specialty pharmaceutical company that develops and commercializes dermatology products. He retains the title of chief operating officer, which he assumed in 2001. Mr. Vontz joined the Palo Alto, Calif., company in 1999 as executive VP.

He replaces Tom Wiggans, who has served as president, CEO, and director of Connetics since 1994. Mr. Wiggans,

who continues to serve as CEO, will assume the role of chairman in 2006.



Drug-Delivery **POOL**

Todd **MACLAUGHLAN**

CIMA Labs Announces Executive Appointment

Todd MacLaughlan has been named corpo-



rate VP and general manager of CIMA Labs, West Chester, Pa., a drug-delivery technology company and subsidiary of Cephalon. He is responsible for the subsidiary's overall operations, with a particular focus on growing the drug-delivery partner business.

Mr. MacLaughlan most recently served as VP, business development and alliance management, at Watson Pharmaceuticals.

He holds a B.S. from the University of Prince Edward Island and a MBA from the Kellogg Graduate School of Management at Northwestern University.

Device/Diagnostic **POOL**

Steven E. **HANSON**

Pace Medical Names CEO

Pace Medical, a medical-device company based in Waltham, Mass., has appointed Steven E. Hanson president and CEO.

Mr. Hanson has more than 26 years of experience in the medical-device field. Most recently, he spent 11 years as president of Zimmer Dental, formerly Sulzer Medica. Previously, he was VP of international for Intermedics.

Dr. Jelle W. **KYLSTRA**

Rita Medical Creates VP, Medical Director Position

Jelle W. Kylstra, M.D., has been named to the position of VP and medical director of Rita Medical Systems, a developer of medical oncology devices based in Mountain View, Calif. In this newly created position, Dr. Kylstra is responsible for expanding awareness about radiofrequency ablation as a treatment for cancer.

Most recently, he held the position of VP, clinical development, for Light Sciences.

A member of the American Society of Clinical Oncology and the American Association for Cancer Research, Dr. Kylstra holds a MBA from Northwestern University, J.L. Kellogg Graduate School of Management, and he received both his M.D. and master of medicines degree from the University of Amsterdam.

Dr. Geoffrey **O'NEILL**

Bio-Matrix Appoints President

Bio-Matrix Scientific Group, San Diego,

has appointed Geoffrey O'Neill, Ph.D., to the role of president. Bio-Matrix is a development-stage company in the business of medical devices and monitoring systems.

Dr. O'Neill is working closely with the company's director of research and development to develop next generation cryo-genic technology and other medical-device technologies. He most recently served as director of stem cell laboratories and scientific research for Cryo-Cell International.

After earning his Ph.D. in immunology from University of Glasgow, Dr. O'Neill completed postdoctoral training in transplantation immunobiology at Memorial Sloan-Kettering Cancer Center.

Stephen W. **SAGON**

CardioFocus Names President and CEO

CardioFocus, Norton, Mass., has appointed Stephen W. Sagon president, CEO, and director. Former President and CEO Jeffrey M. Arnold has retained the position of chairman. CardioFocus develops and supplies laser ablation catheters and systems for the treatment of atrial fibrillation.

Mr. Sagon, who has more than 24 years of experience in the medical-device industry, most recently served as executive VP of CardioNet. He holds a J.D. from the Emory University School of Law and a B.A. in government and philosophy from Franklin & Marshall College. He is a member of the Georgia Bar Association and a member of the Heart Rhythm Association.

Discovery **POOL**

Dr. Page **BOUCHARD**

Archemix Names Senior VP of Preclinical Drug Discovery and Development



Archemix, which discovers and develops aptamer therapeutics, has named Page Bouchard, D.V.M., as senior VP of preclinical drug discovery and development.

Dr. Bouchard has responsibility for directing the company's preclinical pharmacology, drug metabolism, and pharmacokinetics and drug safety efforts.

Before joining Archemix, Cambridge,

Mass., Dr. Bouchard was VP of drug safety evaluation at Millennium Pharmaceuticals.

He received a bachelor's degree from Wesleyan University and a D.V.M. from Tufts University Veterinary School. He trained in veterinary pathology at Cornell Veterinary School and is board certified in veterinary pathology by the American College of Veterinary Pathologists.

Eric L. **DOBMEIER**

Seattle Genetics Promotion Announced



Eric L. Dobmeier has been named senior VP, corporate development, at Seattle Genetics, Bothell, Wash., which discovers and develops monoclonal antibody-based therapeutics to treat cancer and immunologic diseases.

Mr. Dobmeier has been promoted from VP, corporate affairs, and has retained the title of general counsel, a position he has held since joining the company in March 2002.

He is responsible for managing the company's legal affairs, including corporate and intellectual property, as well as its business development and corporate communications activities.

Before joining Seattle Genetics, Mr. Dobmeier was with the law firms of Venture Law Group and Heller Ehrman White & McAuliffe. He holds a law degree from Boalt Hall School of Law, University of California, Berkeley, and an undergraduate degree from Princeton University.

Dr. F. Andrew **DORR**

Nereus Creates Chief Medical Officer Position



Nereus Pharmaceuticals, a San Diego-based drug discovery and development company, has appointed F. Andrew Dorr, M.D., as chief medical officer and senior VP, clinical development and regulatory affairs.

Dr. Dorr, a medical oncologist, is charged with overseeing human trials of Nereus' drug candidates and relations with regulatory authorities.

Most recently, he was the chief operating officer at Salmedix. He is a member of the American Society of Clinical Oncology and the American Association for Cancer Research.

Dr. Dorr earned his medical degree from the University of North Carolina.

Dr. Maria **PARIS**

Enanta Makes Key Appointment to Clinical Development Team



Maria Paris, M.D., has been named senior medical director at Enanta Pharmaceuticals, Watertown, Mass., which uses a chemistry approach and drug-discovery capabilities to create small-molecule, anti-infective drugs.

Dr. Paris most recently worked as medical director for Abbott Laboratories.

She earned her medical degree from Autonomous College of Medical Sciences of Central America of Costa Rica.

Genomics **POOL**

V.W. **BRINKERHOFF III**

Gene Logic Appoints General Manager for Preclinical Contract Research Services



V.W. Brinkerhoff III has joined Gene Logic, Gaithersburg, Md., as senior VP and general manager for the company's preclinical contract research business. Gene Logic provides drug development services to the pharmaceutical industry.

Most recently, Mr. Brinkerhoff was group VP, operations, at Wilson Greatbatch Technologies, a medical-device components manufacturer.

Association **POOL**

Peter **DOLAN**

Kevin **SHARER**

William C. **WELDON**

PhRMA Elects Industry Veterans to Board of Directors

The Pharmaceutical Research and Manu-

facturers of America (PhRMA), Washington, D.C., the trade association representing the country's leading pharmaceutical research and biotechnology companies, has announced key appointments to its board of directors.



Peter Dolan, chairman and CEO of Bristol-Myers Squibb, has been named as the board's chairman-elect.

Since joining BMS in 1988, Mr. Dolan has had line management responsibility in all four of the company's current businesses: consumer products, nutritionals, medical devices, and pharmaceuticals.

He was named president and director in 2000 and became the company's CEO and chairman in 2001.

He earned his B.A. from Tufts University and his MBA from the Amos Tuck School of Business at Dartmouth.



Additionally, Kevin Sharer, chairman and CEO of Amgen, has been appointed treasurer of the PhRMA board.

Mr. Sharer joined Amgen 23 years ago as the company's president, chief operating officer, and member of the board of directors.

He holds a bachelor's degree in aeronautical engineering from the U.S. Naval Academy, a master's degree in aeronautical engineering from the U.S. Naval postgraduate school, and a MBA from the University of Pittsburgh.



William C. Weldon, chairman and CEO of Johnson & Johnson, has been elected chairman of the board of directors of PhRMA.

In his 34 years at J&J, Mr. Weldon has held sales and marketing and executive leadership positions for the company's affiliates and offices worldwide.

In 1998, he was promoted to the executive committee and named the worldwide chairman of J&J Pharmaceuticals. He has served as president and CEO since 2002.

Mr. Weldon holds a bachelor's degree in biology from Quinnipiac University, where he now sits on the board of trustees.

James F. **JORDAN**

Pittsburgh Life Sciences Greenhouse Builds Management Team

James F. Jordan has been named executive-in-residence at the Pittsburgh Life Sciences

Greenhouse (PLSG), a public/private partnership that invests in and supports growing life-sciences companies in the Pittsburgh area.

In this role, Mr. Jordan focuses on early-stage company formation as well as the commercialization of later-stage technologies and opportunities.

Before joining PLSG, Mr. Jordan was a senior VP, marketing and business development, at McKesson.

Agency **POOL**

Erin **ARMSTRONG**

Sean **CORCORAN**

Palio Announces Promotions



Palio Communications, Saratoga Springs, N.Y., has announced account-related promotions. Palio, a subsidiary of inChord Communications, is a full-spectrum advertising and communications agency.



Erin Armstrong has been promoted from senior account executive to account supervisor.

Sean Corcoran has been promoted from account coordinator to assistant account executive.

Angie **BAUERLE**

Nicole **BERG**

Rachel **LOMASZ**

Abelson-Taylor Promotes Three



Abelson-Taylor, an independent medical advertising agency based in Chicago, has appointed Angie Bauerle senior art director for Avonex and Xyotax. She also is working on new business pitches for the agency.

She holds a BFA from the College of Mount St. Joseph in Cincinnati.

Nicole Berg has been promoted to senior copywriter and is primarily responsible for copywriting on Kepivance, she also continues



working on Aloxi. She earned her M.S. in public health from the University of Illinois at Urbana-Champaign.

Rachel Lomasz also has been promoted to senior copywriter. She is the lead writer on the campaigns for Avonex and Aranesp.

Before joining Abelson-Taylor, Ms. Lomasz was a copywriter at BBDO Chicago. She is a graduate of the University of North Carolina at Chapel Hill.



Ken **DEC**
Malcolm **FAULDS**

PreVision Hires Chief Marketing Officer and eMarketing Director



Ken Dec has been named chief marketing officer of PreVision, a multichannel relationship marketing agency based in Lincoln, Mass.

Mr. Dec, a 23-year marketing veteran, has come to PreVision from VIA Group, where he led strategy and business development.



Malcolm Faulds has been named director of e-marketing, responsible for the development of online marketing programs. Most recently, Mr.

Faulds was group account director at Euro RSCG 4D.

Peter J. **DELORENZO**
Qi Interactive Appoints Senior Project Director



Peter J. DeLorenzo, M.P.A., R.Ph., has been appointed senior project director for Qi Interactive. The full-service digital agency is a division of CommonHealth, a Parsippany, N.J.-based healthcare communications organization. Mr. DeLorenzo oversees the development of interactive health relationship marketing programs targeting both consumers and professionals.

Mr. DeLorenzo oversees the development of interactive health relationship marketing programs targeting both consumers and professionals.

Previously, Mr. DeLorenzo was the director of eHealth services at SoftWatch. He is a registered pharmacist, and he holds a B.S. in pharmacy and a M.P.A. in healthcare administration from Long Island University.

LeAnn **DUNCAN-MILLER**

Bill **FILLIPP**

Dr. Isadore **PIKE**

Doug **PLESSINGER**

David **QUERRY**

Navicor Names Senior Staff

The Navicor Group, Columbus, Ohio, a full-service advertising agency focused on oncology and immunology, has made additions to its senior-management team. Navicor is a subsidiary of inChord Communications.



LeAnn Duncan-Miller has been named director of creative services, managing the execution of all work created by Navicor on behalf of its clients. She previously served as the creative services supervisor for GSW Worldwide, Navicor's sister agency.



Bill Fillipp has been appointed senior VP, creative director. He oversees creative development for clients and establishes the creative vision for the agency. Mr. Fillipp most recently was senior VP, group creative director at GSW Worldwide.



Isadore Pike, M.D., has been named medical director, responsible for providing medical and scientific insights. A board-certified oncologist, he previously held leadership positions at Bristol-Myers Squibb, Quintiles Oncology Therapeutics, EMD Pharmaceuticals, and Merix Bioscience.



Doug Plessinger has joined Navicor as VP, account services, responsible for oversight of key accounts and management of client relationships. He previously served as VP, account ser-



vices, at GSW Worldwide. Mr. Plessinger is a licensed clinical pharmacist.

David Querry has been named VP, account services. He oversees key accounts and manages relationships with clients.

He previously was VP, account director, at GSW Worldwide.

John **FINAN**
Roberta **LIPP**

Adient Announces Appointments



John Finan has been named executive VP, managing director at Adient, a CommonHealth professional advertising and promotion agency located in Wayne, N.J.

Mr. Finan supervises account management teams in the creation and implementation of professional marketing programs. Previously, he was senior VP, managing director of medical education services at Cardinal Health.



Roberta Lipp has been promoted to account executive, responsible for supporting the development of professional marketing initiatives for her clients. Ms. Lipp joined Adient more than four years ago as a traffic coordinator and most recently served as a traffic manager.

Todd **FORTE**
Ginger **HALL**
Jeff **HOYAK**
Olga **SILVA**

MCS Announces Leadership Restructuring



MCS, a healthcare public-relations firm based in Bedminster, N.J., has appointed Todd Forte to the position of executive VP.

Before joining the company, Mr. Forte worked as assistant

director of communications at Novartis Pharmaceuticals.



MCS also has announced the appointment of Jeff Hoyak as president and has expanded its executive committee.

Mr. Hoyak has been with MCS for 10 years, most recently serving as executive VP. Previously, he held public affairs positions at Lederle Laboratories and reporting and editing positions at Today Newspapers.

Additionally, MCS has appointed two new VPs — Ginger Hall and Olga Silva — to join Mr. Hoyak, Mr. Forte, and Joe Boyd, CEO and founder, on the company's executive committee.

Ms. Hall has 10 years of experience in pharmaceutical public relations. She has implemented a variety of programs from pre-approval communications to new drug approvals.



Ms. Silva has been with MCS for 13 years. Along with overseeing the agency's operations, Ms. Silva specializes in clinical communications initiatives and provides fiscal management counsel.

As part of the executive committee, Ms. Hall, Ms. Silva, and Mr. Forte serve as account team leaders, working directly with agency clients.

Mr. Boyd and Mr. Hoyak provide counsel to all MCS account teams and their clients.

Paul D. GIROUX

Sudler & Hennessy Names Head of Consolidated Brand Planning Department



Paul D. Giroux has been appointed executive VP and director of brand planning and market analysis at Sudler & Hennessy, a New York-based global healthcare marketing and communications organization and

WPP company.

Mr. Giroux coordinates the activities and resources of the medical affairs department, the strategic planning group, market research, information services, and the analytics team. This unified group provides integrated market analysis and strategic solutions to all Sudler & Hennessy clients.

Mr. Giroux joins the company from Saatchi & Saatchi, where he served as strategic mar-

keting director across several brands. Previously, he worked as VP of corporate marketing and business development at Aventis.

Gicell HERNANDEZ

TLM West Appoints Account Group Supervisor



Gicell Hernandez has joined Torre Lazur McCann (TLM) West as account group supervisor, responsible for overseeing the agency's participation in the launch of Pulmiq inhalation solution. TLM West, a wholly owned subsidiary of TLM Healthcare Worldwide, offers integrated, core advertising and specialty services.

Ms. Hernandez has joined the San Diego-based agency from Pacific Communications, where she was account supervisor.

Ms. Hernandez holds a MBA from the University of California, Irvine, as well as a B.A. from California State University of Fullerton.

Dr. Peter MIRABILE

Fission Hires Medical Director



Fission Communications, New York, has hired Peter Mirabile, M.D., as medical director.

He is responsible for providing medical guidance for key Fission accounts.

Before joining the McCann-Erickson Healthcare Worldwide company, Dr. Mirabile participated in clinical clerkships throughout the United Kingdom.

William J. REILLY JR.

RealTime Media Appoints President and CEO



William J. Reilly Jr. has joined RealTime Media as president and CEO. The company, based in King of Prussia, Pa., develops compliance-based marketing campaigns for the pharmaceutical industry.

Most recently, Mr. Reilly worked with the Chesterbrook Growth Partners as an independent consultant to private equity firms.

Consulting POOL

Terry WACHALTER

Flaum Adds to Senior Management Team



Terry Wachalter has been named senior partner at Flaum Partners, a New York-based business development consultancy.

Ms. Wachalter previously served as executive VP, director of global operations for Euro RSCG Life. Additionally, she served as executive VP of operations and chief financial officer for Robert A. Becker Euro RSCG.

CRO POOL

Dr. Rose BLACKBURNE

Dr. Marc CAPOBIANCO

Dr. Harish DAVE

Dr. Richard OH

Dr. Lori STONE

Dr. Neddie ZADEIKIS

Quintiles Adds Therapeutic Experts to Staff

Quintiles Transnational, Research Triangle Park, N.C., has added six physicians to its medical and scientific services organization, bolstering the company's strength in major therapeutic areas.

Rose Blackburne, M.D., is a board-certified obstetrician/gynecologist with more than 10 years of clinical experience in reproductive health.

She received her M.D. from Morehouse School of Medicine and completed her ob/gyn residency at Columbia Presbyterian Medical Center, Harlem Hospital. She is working in Quintiles' Rockville, Md., office.

Marc Capobianco, M.D., has joined the company's San Diego office from the University of California at San Diego, where he was assistant clinical professor in the department of psychiatry and associate medical director for the Affiliated Research Institute.

Board certified in both psychiatry and neurology, Dr. Capobianco studied medicine at New York Medical College and completed residencies in neurology at UC-Irvine and psychiatry at UC-San Diego.

Harish Dave, M.D., most recently served as associate professor of medicine at George Washington University and assistant chief of hematology at the VA Medical Center in Washington, D.C.

Dr. Dave studied medicine at the University of Sheffield, England, and he completed an internal medicine residency in London. He is board certified in internal medicine, hematology, and medical oncology. He is based in the Rockville, Md., office.

Richard Oh, M.D., who has therapeutic experience in critical care, trauma, general medicine, cardiovascular, and respiratory disease, has joined Quintiles' office in Research Triangle Park.

Most recently, he served as a hospitalist physician at Johnston Memorial Hospital in North Carolina. Dr. Oh earned his M.D. from the University of Pittsburgh School of Medicine and completed a residency in family and community medicine at Womack Army Medical Center.

Lori Stone, M.D., a board-certified neurologist, has joined Quintiles from the Centre for Health Care in San Diego, where she was president of the medical group. She earned her M.D. from the State University of New York at Stony Brook, where she also completed her internship in internal medicine.

She completed her residency in neurology and a fellowship in electromyography/neuromuscular disease at the University of California at San Diego. Dr. Stone is working in Quintiles' San Diego office.

Neddie Zadeikis, M.D., has joined the company's Parsippany, N.J., office. Dr. Zadeikis is board certified in infectious disease and internal medicine.

Most recently, she served as the medical director of infectious disease research at Ortho-McNeil Pharmaceuticals.

Dr. Zadeikis received her M.D. at Rush Medical College and completed an infectious disease residency at Rush-Presbyterian-St. Lukes Medical Center in Chicago.

Dr. Leslie **BUNCE**

Dr. Carl M. **LEVENTHAL**

INC Research Builds Medical Affairs Team

INC Research, Raleigh, N.C., has appointed two new directors to its medical-affairs team. Leslie Bunce, M.D., has been named director of medical affairs, and Carl M. Leventhal, M.D., has been named senior director of medical affairs.

INC Research is a global contract research organization specializing in central nervous system, oncology, and pediatric clinical research.

Dr. Bunce and Dr. Leventhal provide specialized therapeutic expertise and medical consultation in the development and administration of clinical trials.

Dr. Bunce is board certified in internal medicine and hematology. Before joining INC Research, she served as a medical consultant on an independent review board.

Dr. Leventhal is a board-certified neurologist and former research physician. Most recently, he was a consultant to pharmaceutical companies, biotechnology companies, and academic institutions developing neurological compounds.

Kyle **MCALLISTER**

Radiant Hires VP, Business Development



Kyle McAllister has been named VP of business development for Radiant Research, a Bellevue, Wash.-based contract research organization.

Radiant provides Phase I-IV clinical drug-development services to the biopharmaceutical industry.

As the leader of Radiant's specialized business development team, Mr. McAllister directs the sales and marketing functions for the company's early-phase, late-phase, and clinical-development business units.

Before joining Radiant, he was VP of business development for MDS Pharma Services.

Mr. McAllister holds a B.S. degree from the University of Nebraska.

Susan **ROMBERG**

Chiltern International Appointment Supports U.S. Focus

As part of its continued U.S. growth, London-based CRO Chiltern International has appointed Susan Romberg as VP of East Coast operations.

Ms. Romberg is responsible for locating the East coast office facility, setting up operations, hiring appropriate staff, and working with the business development team to secure new work for the company.

Ms. Romberg previously worked as a clinical study coordinator with the University of Pennsylvania, and she has held leadership positions in pharmaceutical and contract research companies.

Contract-Sales **POOL**

Andy **BALDWIN**

Julia **KELLY**

Brad **PATTEN**

Ventiv Pharma Announces Promotions



Ventiv Pharma Services, Somerset, N.J., has promoted Andy Baldwin to senior director of network services. Mr. Baldwin is responsible for the company's entire voice and data communications infrastructure.

Ventiv Pharma, a division of Ventiv Health, provides sales, marketing, and compliance solutions.



Julia Kelly has been promoted to the position of executive director, marketing. Ms. Kelly leads the marketing effort for all Ventiv Health companies and divisions, provides brand-marketing consultation, and serves on the Ventiv Pharma senior management team.

Brad Patten has been promoted to VP, marketing and corporate development. He serves on the company's steering and senior management teams.



Mr. Patten joined Ventiv in 1998.

Media **POOL**

Lynn **CHAIKEN**

Priscilla **VALLS**

Rich **WELLEN**

Jennifer **WILLEY**

RealAge Expands Sales Team

RealAge, a San Diego-based consumer-

health media company, has announced several new appointments to its sales team.

Lynn Chaiken, who previously worked as the VP, national sales, at Beliefnet, has been added to the RealAge sales team.

Priscilla Valls has joined RealAge from eDiets, where she was director of advertising sales.

Rich Wellen has joined the team from Imagitas, where he was manager of New England sales.

Jennifer Willey, who most recently worked at Yahoo as key account executive for its prescription and consumer packaged goods business, has joined RealAge.

Joe DECICCO

Carson MCBRAYER

HMP Adds to Sales Staff



HMP Communications, a medical media company specializing in the care of the senior patient population, has added two sales professionals to its staff.

Joe DeCicco has joined the Malvern, Pa.-based company as national accounts manager for *Annals of Long-Term Care*.

Previously, Mr. DeCicco worked with Eli Lilly as a sales representative and Novacare as a physical therapist.

Also, Carson McBrayer has been added to the HMP staff as an account representative, responsible for accounts in the cardiovascular division, including *Journal of Invasive Cardiology*, *Cath Lab Digest*, *EP Lab Digest*, and *Vascular Disease Management*. Ms. McBrayer formerly worked with Smith & Nephew as a sales assistant.

Dr. Lauren GALLAGHER

Dr. Alex LOEB

Kelly REITH

Dr. Peter RITTENHOUSE

Dr. Kevin RYDER

Complete Healthcare Communications Announces Key Editorial Appointments

Complete Healthcare Communications, Chadds Ford, Pa., a strategic medical-communications company that serves the pharmaceutical and biotechnical industries, has promoted Lauren Gallagher, R.Ph., Ph.D., to editorial director from editorial manager.



In this position, Dr. Gallagher manages the company's entire editorial department, overseeing more than 40 staff medical directors, medical writers, and editors.

The strategic medical communications company also has promoted Alex Loeb, Ph.D.; Kelly Reith, M.S., MBA; Peter Rittenhouse, Ph.D.; and Kevin Ryder, Ph.D., to senior medical directors.

Emily LEONARD

Intellisphere Announces Promotion



Emily Leonard has been named managing editor of the *MD Net Guide* series of medical journals at Intellisphere, Plainsboro, N.J., a publisher of print journals and online resources for physicians.

Ms. Leonard has been promoted from assistant editor and is responsible for managing the daily flow of article and freelance assignments to various editors and production departments.

Nick LUCIANO

QuadrantHealthCom Names Account Manager

Quadrant HealthCom has named Nick Luciano account manager of *Physicians' Travel & Meeting Guide*, one of the seven medical journals published by the Chatham, N.J.-based healthcare communications firm.

Mr. Luciano is responsible for selling advertising pages.

His background includes four years of experience in media planning.

Most recently, he was media planner at Conectics, a division of Thomas Ferguson Associates.

Shannon MILLER

Tony PERRAGLIA

Heather WOOD

Jobson Announces Appointments

Shannon Miller has been named VP of business development for Jobson Education Group, Englewood, Colo.

Jobson Education Group is the medical-

education division of Jobson Publishing, which is comprised of medical publishing, education, and communication companies serving healthcare providers worldwide.

Most recently, Ms. Miller was account director, new business development, at Armand Scott.

Previously, she spent several years in pharmaceutical sales at GlaxoSmithKline.

Ms. Miller holds a B.A. in communications from the University of North Carolina at Wilmington.



Tony Perraglia has joined Jobson Medical Group as associate publisher of *Clinician News* and *Clinician Reviews*. The Bloomfield, N.J.-company is the medical publishing arm of Jobson Publishing.

Mr. Perraglia previously worked at Haymarket Media, where he served as national accounts manager on *The Clinical Advisor*.



In other company news, Heather Wood has joined *Clinician News* and *Clinician Reviews* as NP/PA education programs director.

She is responsible for selling customized programs to pharmaceutical clients.

Ms. Wood most recently served as account director, education development, at Jobson's Ethecol Institute. Previously, she held positions at Thomson Medical Economics, Multimedia Healthcare/Freedom, and Ortho-McNeil Pharmaceutical.

Medical-Education POOL

Wendy C. ASHMEN

Donna M. DARDINE

Warren A. DARDINE

Adam B. SERODY

DHC Announces New Division and Leadership Change

Dimensional HealthCare (DHC), Cedar Knolls, N.J., a provider of late-phase medical research to the pharmaceutical and medical-device industries, has announced staff appointments following the formation of the DHC clinical-education group.

The new group, based in Newtown Square, Pa., provides credentialed education for the healthcare industry.



Wendy C. Ashmen has been appointed as program director for the clinical-education group. Her responsibilities include developing and implementing educational programs, helping to form and facilitate thought leader councils, and ensuring that all educational programs are in compliance with accreditation guidelines.

Before joining the company, Ms. Ashmen was director of national programs for Programs in Medicine.

She holds a B.A. in history from Rutgers University.




Donna M. Dardine has been hired as group account supervisor. She is the account team liaison to all of the clinical education group's industry supporters, responsible for status reports, proposals, billing, and program timelines and budgets.

Ms. Dardine comes to DHC from Programs in Medicine, where she was account manager.



Additionally, Warren A. Dardine has been named senior VP of the DHC clinical-education group. Before joining DHC, Mr. Dardine was president of Programs in Medicine.

He earned a B.S. in biology from Widener University and attended the University of Pennsylvania School of Medicine.



In other company news, Adam B. Serody has joined DHC as VP, clinical solutions. He is responsible for expanding and diversifying DHC's client base, while working with the clinical and scientific affairs teams to ensure clinical infrastructure and strategic planning for Phase IIIb, IV, and community-based trials.

Mr. Serody has joined DHC from Paragon Biomedical where he worked in both clinical services and business development.

He holds a B.A. in experimental psychology from California State University at San Marcos and a certification in drug development and clinical research from Mercer College.

Kevin FLYNN

Fusion Appoints Managing Director



Kevin Flynn has been promoted to managing director for Fusion Medical Education, a medical-education company based in Salem, Mass., and a member of the AXIS Healthcare Communications group of companies.

Mr. Flynn, formerly senior VP of medical affairs and scientific services, has taken over for Patricia Patrick, who has retired.

Since joining the company five years ago, Mr. Flynn has supervised the creation and implementation of strategic publication plans for numerous products in several therapeutic areas.

He holds B.A. degrees in journalism and Spanish from Marquette University and a M.A. in English from the University of Houston.

Sarah MOONEY

Reggi VEATCH

Dr. Eve WILSON

INNOVIA Creates Three Director Positions



INNOVIA Education Institute, Columbia, Md., has promoted Sarah Mooney to the newly created position of director of program services.

Working with in-house teams and clients, Ms. Mooney leads the development, implementation, and accreditation of a wide variety of programming for INNOVIA, an accredited provider of continuing medical-education services and wholly owned subsidiary of Columbia MedCom Group.

Ms. Mooney most recently served as managing editor and program director.



Additionally, Reggi Veatch has been promoted to director, editorial and scientific services, at the company. In this newly created position, Ms. Veatch oversees the development and execution of a wide variety of continuing medical education programs.

Together with Ms. Mooney, she is responsible for ensuring the strategic direction, quality, and profitability of all INNOVIA programs.

Ms. Veatch most recently was director of editorial services for Columbia Medcom Group's promotional medical marketing subsidiary.



Eve Wilson, Ph.D., ELS, has been named director, continuing medical-education services, another newly created role. Previously a senior medical writer and manager of scientific affairs, Dr. Wilson helps develop, manage, and accredit educational programs for physicians and other healthcare professionals.

Service POOL

Dr. Stephen J.

BOCCUZZI

PharMetrics Names VP, Chief Scientific Officer

PharMetrics has announced that Stephen J. Boccuzzi, Ph.D., MBA, FAHA, has been named VP and chief scientific officer. Based in Watertown, Mass., PharMetrics provides market intelligence solutions to the pharmaceutical, biotech, medical-device, and health-plan sectors.

Dr. Boccuzzi also is managing the company's new Mid-Atlantic hub in the greater Philadelphia area, providing leadership to a growing team of scientists, clinicians, and analysts. Most recently, he worked for Aetna Health Information Solutions as chief scientific officer and head of pharmaceutical operations.

He holds a master of science degree from Catholic University, a MBA from St. Joseph's University, and a Ph.D. from the University of Maryland.

Anna BUCKLEY

Nichole CAMPANALE

Sara HENDLER

Kharen JONES

Lauren KUSHNER

Communications Media Announces Promotions

Communications Media (CMI), King of

Prussia, Pa., an advertising media and promotions planning firm focused on the pharmaceutical industry, has made several key promotions.

Anna Buckley has been named senior supervisor, media strategies. During her seven years with CMI, Ms. Buckley helped found the firm's New York office.



Nichole Campanale has been promoted from media assistant to assistant media planner. She works on campaigns for Nexium, Humira, and all Cephalon products.

Sara Hendler has been promoted to media planner. Ms. Hendler supervises campaigns for Arimidex, Faslodex, Casodex, Zoladex, Nexium, and Actiq.



Kharen Jones has been promoted to media supervisor. She has been with CMI for four years and supervises campaigns for Seroquel, Provigil, and all Abbott products.

Lauren Kushner has been promoted to media planner. She works on all Schwarz Pharma products, as well as Abbott's Kaletra.



Eric A. **CORKHILL**

TMG Health Names Sales and Marketing VP

TMG Health, a provider of outsourced Medicare and Medicaid claims management services based in King of Prussia, Pa., has appointed Eric A. Corkhill VP, sales and marketing. Mr. Corkhill assumes responsibility for expanding TMG Health's customer base, growing revenue with existing customers, and developing new markets for the company's core products.

For four years before joining TMG Health, Mr. Corkhill headed the sales and development team of Sentillion, a healthcare information technology firm.

Patricia **DEVEREUX**

Joseph **GRISPO**

Brian **LEISER**

Daniel **MUDGETT**

Medidata Builds Operations Staff

Medidata Solutions, New York, a provider

of electronic clinical data-management solutions, has announced several appointments to its operations staff.

Patricia Devereux has been named VP, implementation services. She oversees all aspects of project management for global implementations of the company's RAVE product.

Ms. Devereux previously worked at Oracle as the consulting practice director in the life-sciences group.

Joseph Grispo has been named senior VP, operations, responsible for trial implementation, technology transfer to existing customers, clinical-data integrity, and compliance and customer service. Mr. Grispo most recently served as senior VP, global services, for Global Logistics.

Brian Leiser also has been appointed VP of implementation services with responsibility for all aspects of project management for global RAVE implementations.

Before joining Medidata, Mr. Leiser was director of life-sciences services at Siebel Systems.

In other company news, Daniel Mudgett has been appointed VP of clinical resources. Mr. Mudgett is responsible for the implementation services of electronic data management.

Before joining Medidata, he worked at Amgen, where he was associate director of clinical data management.

Ihab **GHALY**

James **O'DONNELL**

Laurie **PLOTCH**

J. Knipper and Company Announces Appointments



J. Knipper and Company has promoted Ihab Ghaly to the role of VP of sampling and regulatory affairs. J. Knipper, Lakewood, N.J., provides marketing support services to the healthcare industry.

Mr. Ghaly has been with the company since early 2001 and has played a critical role in the growth of its sampling business.



Also at the company, James O'Donnell has been named to the position of group team leader, materials management.

Previously, Mr. O'Donnell was with Baxter Healthcare as senior

production planner.

He holds a B.S. in business administration from Mount Saint Mary's College.



Additionally, Laurie Plotch has been appointed VP of sales. Most recently, Ms. Plotch was director of business development in the specialty services division at McKesson.

She holds a M.A. in organizational management from the University of Phoenix and a bachelor's degree in education and history.

Grant **JACKSON**

Dr. Chris **KROEGER**

Aurora Funds Promotes Principals

The Aurora Funds, a seed and early-stage venture capital firm based in Durham, N.C., has promoted Grant Jackson and Chris Kroeger, M.D., to principals. Both continue to support existing portfolio companies and to identify new life-sciences investment opportunities.

Mr. Jackson, who joined Aurora in May 2004 as a senior associate, has focused on sourcing new investment opportunities in the healthcare services and medical-device industries.

He earned a MBA with distinction from Northwestern University's Kellogg School of Management.

Dr. Kroeger joined Aurora in September 2003 as an associate and has worked closely with the investment team to source and evaluate prospective deals.

He holds a B.A. in biology from Harvard University, a M.D. from Stanford University School of Medicine, and a MBA from Harvard Business School.

Dr. Martin D. **MADAUS**

Millipore Appoints Chairman



Martin D. Madaus, Ph.D., has been named chairman of the board of Millipore, a multinational, high-technology bio-science company based in Billerica, Mass.

Dr. Madaus became Millipore's CEO and president in January of this year.

Before joining Millipore, Dr. Madaus was responsible for the Roche Diagnostics business in North America.

Dr. Madaus has assumed the role of chairman of the board from Francis J. Lunger.

Jeff **MARTINI**

SciQuest Names Senior VP,
Worldwide Sales



Jeff Martini has joined SciQuest, Research Triangle Park, N.C., as senior VP of worldwide sales. SciQuest helps customers gain greater control and visibility over their spend by connecting their procurement and financial

systems to suppliers.

He is responsible for global sales strategy, operations, and execution for SciQuest's spend-management solutions.

Mr. Martini most recently served as VP of worldwide sales for VirtualEdge.

Christa **NICHOLAS**

Wayne **WATERFIELD**

CHS Adds Two Marketing
Professionals

CHS, a contract marketing firm serving the pharmaceutical and biotechnology industries, has added Christa Nicholas and Wayne Waterfield to its team of marketing professionals.

Ms. Nicholas and Mr. Waterfield are responsible for providing a broad range of marketing solutions and best practice insights to CHS clients. CHS is a subsidiary of inChord.

Ms. Nicholas has joined the Scottsdale, Ariz.-firm from Aradigm, where she was director of marketing.

She earned her bachelor's degree from Princeton University.



Mr. Waterfield has returned to CHS after serving as director of the business solutions group at Cardinal Health's healthcare marketing services unit.

He holds a master's degree from Northeastern University and a bachelor's degree from Hamilton College.

Allen **STEGALL**

Group DCA Names VP,
Electronic Publishing and Market
Research

Allen Stegall has been appointed VP of electronic publishing and market research for Group DCA, an online healthcare communications company based in Montclair, N.J.



He most recently was president of Dudnyk Healthcare Group.

Mr. Stegall received a bachelor of science degree in physical science as well as a MBA from Arkansas State University.

Rebecca **WHEELER**

Advanced Health Media Appoints
Operations Manager



Advanced Health Media, Union, N.J., has named Rebecca Wheeler operations manager.

Advanced Health Media is a full-service marketing and communications firm that provides products, services,

and events to the medical and pharmaceutical industries.

Ms. Wheeler, who was promoted from senior project supervisor, develops and implements plans and processes to provide highly effective speaker programs and promotional meetings for key clients.

She is responsible for project budgets, as well as managing the training and professional development of her team.

Ms. Wheeler holds a B.A. in psychology from Taylor University.

Dr. Steven D. **WOOD**

J.D. Power Appoints Senior VP,
General Manager of
Healthcare Division



Steven D. Wood, Ph.D., has been named senior VP at J.D. Power and Associates and general manager of the healthcare division, based in Mesa, Ariz.

J.D. Power, Westlake Village, Calif., is a global marketing information services firm.

Dr. Wood is focused on developing products, broadening customer relationship strategies, evaluating alliances, and coordinating mergers and acquisitions to help the company better serve clients in the healthcare sector.

Dr. Wood holds bachelor's and master's degrees in business from San Diego State University.

He earned his Ph.D. in quantitative business analysis from the University of Wisconsin-Madison.

Technology/Web **POOL**

Dr. Gary **GABRIEL**

LifeTree Names VP, Sales and
Business Development



Gary Gabriel, Ph.D., has been appointed VP of sales and business development of LifeTree Technology, Temecula, Calif., the e-clinical services division of FFF Enterprises. He is responsible for supporting and expanding the company's client base using its eClinical suite.

Kevin M. **KING**

President and CEO Appointed at
Thomson Healthcare Division



Thomson Scientific and Healthcare has appointed Kevin M. King as president and CEO of its technology healthcare business, Stamford, Conn.

Mr. King was VP and general manager of global clinical systems at GE. He holds a MBA from the University of Southern

New Hampshire.

Steve **POWELL**

Jason **REYNOLDS**

Phase Forward Announces
Leadership Changes



Steve Powell has been promoted to VP, worldwide sales for Phase Forward, Waltham, Mass., a provider of data-management solutions for clinical trials and drug safety. He assumes responsibility for the worldwide sales function in addition to retaining his previous duties as VP and general manager, international.



Jason Reynolds has been named VP, North American sales. He recently served as director, North American sales. ♦

Please send your personnel announcements to feedback@pharmavoices.com.